Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients.

Sato T. et al, (2025), Clin Cancer Res

Patient characteristics, serious disease diagnoses, and incidental findings in individuals with non-specific symptoms referred to the Suspected CANcer (SCAN) Pathway: a prospective cohort study in England

Friedemann Smith C. et al, (2025), The Lancet Primary Care, 100019 - 100019

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).

Wong MK. et al, (2025), J Clin Oncol

Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England.

Buckell J. et al, (2025), Br J Cancer

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.

Milotay G. et al, (2025), Nat Med

Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients With BRAF V600-Mutant Metastatic Melanoma.

Dummer R. et al, (2025), Clin Cancer Res

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.

Weber JS. et al, (2025), J Clin Oncol, 43, 929 - 937

Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms.

Sivakumar S. et al, (2025), Nat Commun, 16

Chemotherapy-based treatment of metastatic melanoma

Atkins MB. et al, (2024), Cutaneous Melanoma, Fifth Edition, 693 - 714

Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity.

Go S. et al, (2024), Elife, 13

Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity

Go S. et al, (2024), eLife, 13

Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial.

Scanlon E. et al, (2024), ESMO Open, 9

Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis.

Jackson A. et al, (2024), Lancet Oncol, 25, 1476 - 1486

Cytomegalovirus infection protects against metastatic melanoma and modulates oncological outcome and toxicity to checkpoint immunotherapy

Milotay G. et al, (2024)

A retrospective analysis of the validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries

Jackson A. et al, (2024), The Lancet Oncology

Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.

Hamid O. et al, (2024), J Clin Oncol, 42, 2928 - 2938

Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination.

Watson RA. et al, (2024), J Immunother Cancer, 12

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.

Luke JJ. et al, (2024), J Immunother Cancer, 12

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.

Elez E. et al, (2024), BMC Cancer, 24

Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.

Larkin J. et al, (2024), Cell Rep Med, 5

Load More

1
2
3
4
5
6
7
...
»